Basecamp Research Raises $140M Series C for AI-Designed Medicines

Basecamp Research announced $140M in Series C financing on September 23, 2026. Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.

Round details

The financing includes backing from S32, NVIDIA, Menlo Ventures Anthology Fund, NATO Innovation Fund. The company did not publish a valuation with the announcement.

Round: Series C
Capital announced: $140M
Headquarters: London, UK and Boston, MA

How the company plans to use the capital

Basecamp Research will train a new generation of its EDEN biological foundation models, move an AI-designed therapeutic pipeline toward clinical development beginning with in vivo cell therapy, and expand pharmaceutical partnerships.

Why this matters for GTM teams

The financing shows capital moving from general-purpose biological models toward companies pairing proprietary training data with programs that can progress into drug development.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Basecamp Research corrected Series C announcement.